InnoCare Pharma Executive and Leadership Team

Nghia Ba, the Chief Executive Officer at InnoCare Pharma, directs the overarching corporate strategy and operational execution. This leadership role involves guiding the company's mission to develop innovative drugs for malignant tumors and autoimmune diseases, ensuring alignment with global market demands. Ba oversees the integration of research and commercialization capabilities, fostering an environment where scientific discovery translates into patient benefit. The Chief Executive Officer's focus remains on advancing the pipeline and securing InnoCare Pharma's position as a leader in delivering high-quality, innovative medicines worldwide. Nghia Ba drives the company's commitment to addressing significant unmet clinical needs through pioneering therapeutic solutions.

Xin Fu, the Chief Financial Officer at InnoCare Pharma, manages all financial operations and strategic financial planning. This executive oversees capital allocation, investor relations, and the financial health of the organization, ensuring resources are effectively deployed to support drug development and commercialization efforts. Fu's responsibilities include maintaining robust financial controls and driving fiscal discipline across all departments. The Chief Financial Officer plays a critical part in evaluating investment opportunities and managing the company's financial performance to support its growth objectives in the pharmaceutical sector. Xin Fu ensures the financial stability required for InnoCare Pharma to pursue its mission of creating first-in-class or best-in-class therapies for global patients.

Qiang Zhou, the Chief Medical Officer at InnoCare Pharma, leads the clinical development and medical affairs strategy. This role is central to advancing the company's pipeline in hematological malignancies, autoimmune diseases, and solid tumors, ensuring that therapeutic candidates meet rigorous clinical standards. Zhou oversees the design and execution of clinical trials, guiding the transition of innovative drug candidates from research to regulatory submission. The Chief Medical Officer's expertise is crucial for identifying and prioritizing significant unmet clinical needs, driving the development of therapies that offer substantial patient benefits. Qiang Zhou ensures InnoCare Pharma's commitment to delivering high-quality, innovative medicines is realized through sound medical and scientific leadership.

Kevin Gao, the Chief Operations Officer at InnoCare Pharma, directs the company's operational infrastructure and execution. This leadership position involves optimizing manufacturing processes, supply chain management, and ensuring the efficient delivery of pharmaceutical products to global markets. Gao oversees the integration of research and commercialization capabilities, translating scientific innovation into tangible patient access. The Chief Operations Officer's focus is on enhancing operational efficiency and scalability to support InnoCare Pharma's ambitious development goals. Kevin Gao ensures that the company's comprehensive capabilities are leveraged effectively to create and deliver best-in-class therapies, reinforcing the commitment to addressing unmet clinical needs worldwide.